Why Act Now? - Corporate Integrity Agreement Fines Compliance Violations

I GLASS Method™ - I GLASS Field Based Monitoring Program^® - Why act now?


Biopharmaceutical companies are experiencing heightened government prosecution of compliance violations:

		Possible exclusion and debarment from government medical program payments

		Increasingly large fines and penalties that deplete resources

		Intrusive oversight from Corporate Integrity Agreements

		Civil and criminal prosecution of individuals

		Loss of public and stakeholder trust

I GLASS™ bridges the gap between compliance policies and compliance conduct